中国人群CYP4F2基因多态性对华法林抗凝作用的影响  

Effect of CYP4F2 Polymorphism on Warfarin Anticoagulant in Chinese Population

作　　者：张亚同[1] 梁欣[1,2] 董凡[1] 郑子恢[1] 胡欣[1] 李可欣[1] 杨莉萍[1] 

机构地区：[1]卫生部北京医院药学部,北京100730 [2]北京通州潞河医院药剂科,北京101149

出　　处：《临床药物治疗杂志》2014年第1期41-45,共5页Clinical Medication Journal

基　　金：卫生行业科研专项基金"药物使用安全与输血安全相关技术与标准"(200902008-03);国家科技部"十一五"重大新药创制"心脑血管疾病新药临床评价技术平台研究"(008ZX09312-005)

摘　　要：目的:研究中国人群中CYP4F2基因多态性对华法林抗凝作用的影响。方法:本研究纳入我院应用华法林进行抗凝治疗的患者,对患者CYP4F2基因多态性位点用连接酶检测反应进行检测,以国际标准化比值(INR)作为监测指标,统计学分析基因位点的多态性与华法林用药剂量个体间差异的相关性。结果:207例样品中,CYP4F2基因突变率为22.2%,其中杂合子分型为35.7%,且达到遗传平衡。不同基因分型组间的华法林剂量未见显著性差异,但是携带T的患者华法林稳定剂量有逐步升高的趋势。结论:CYP4F2基因多态性对华法林稳定期剂量有影响但不显著。Objective： To study CYP4F2 polymorphisms on the anticoagulant effect of warfarin in Chinese population. Method： Patients undergoing warfarin anticoagulation therapy in Beijing hospital were included whose CYP4F2 gene polymorphisms were detected with LDR（ligase detection reaction） and INR （international normalized ratio） were monitored. Relationship between CYP4F2 gene polymorphisms and warfarin stable dose was statistical y analyzed. Result： 207 patients were included in which CYP4F2 gene mutation rate was 22.2% and heterozygous type was 35.7%, meeting Hardy-Weinberg equilibrium balance. Warfarin dose in different genotype groups was no signiifcantly different but there was an increasing trend in the T carriers. Conclusion：There is no signiifcant effect of CYP4F2 polymorphism on stable dosage of warfarin.

关 键 词：华法林 连接酶检测反应 CYP4F2 国际标准化比值 基因多态性 CYP4F2 

分 类 号：R97[医药卫生—药品]